Alfa Cytology is dedicated to providing comprehensive solutions for the creation of highly specific and potent bispecific antibodies, with a focus on optimizing antibody design, enhancing specificity, and improving efficacy, thus providing valuable tools for researchers involved in pancreatic cancer research.
Introduction to Therapeutic Bispecific Antibody
Therapeutic bispecific antibodies (bsAbs) are engineered proteins that possess the ability to simultaneously bind two distinct antigens, and this dual-binding ability gives them unique advantages over monoclonal antibodies, including higher selectivity and potency. This higher selectivity makes them ideal for therapeutics that require high specificity. The preparation of bispecific antibodies involves sophisticated techniques such as hybridoma technology, recombinant DNA technology, and chemical conjugation methods. These antibodies can be designed to bring immune cells into proximity with cancer cells, thereby facilitating targeted immune responses.
Fig. 1 Overview of structure and target selection of bispecific antibodies. (Sun Y, et al, 2023)
Classification of Bispecific Antibodies
According to structure, bispecific antibodies can be divided into two categories: IgG-Based bsAbs and Fragment-Based bsAbs.
- IgG-based bsAbs. Structure mimics natural IgG antibodies, comprising two heavy chains and two light chains with an Fc region.
- Fragment-based bsAbs. Composed of small antigen-binding fragments, often scFv (single-chain variable fragment) or sdAb (single-domain antibody) elements.
Fig. 2 Representative bispecific antibodies and their format. (Sun Y, et al, 2023)
Therapeutic Bispecific Antibody for Pancreatic Cancer
| Bispecific Antibody | Company | Target | Phase |
|---|---|---|---|
| AMG 424 | Amgen | CD3 and CLDN18.2 (Claudin 18.2) | Phase I/II |
| REGN1979 | Regeneron | CD3 and CD20 | Phase I/II |
| XmAb14045 | Xencor | CD3 and CD123 (Interleukin-3 receptor alpha chain) | Phase I |
| ABBV181 | BMS | PD-1 and T-cell receptor (TCR) or tumor-associated antigen | Phase I/II |
| DuoBody-CT040 | Genmab | CD3 and CTLA-4 | Phase I |
Our Services
Alfa Cytology's services involve a complete development pipeline from antigen design and immunization to antibody purification and characterization. We are committed to providing researchers with reliable and specific therapeutic bispecific antibody development services to aid in preclinical research and therapy development for pancreatic cancer.
Target Selection
Our bispecific antibody development services target key targets for pancreatic cancer therapy to improve specificity and efficacy. These targets include:
In therapeutic bsAbs development for pancreatic cancer, the selection of targets and target combinations is critical to effectively leverage the unique dual-binding capability of bsAbs. Here are some of the key targets and target combinations we offer:
- HER2 and C-Met
- Fibroblast Activation Protein (FAP) and Interleukin-6 Receptor (IL-6R)
- Claudin 18.2 and PD-1
- PD-1 and Lymphocyte Activation Gene-3 (LAG-3)
Multiple Bispecific Antibody Format
Alfa Cytology can design a variety of bispecific antibody forms to meet different research and therapeutic needs, including:
- IgG-like bispecific antibodies
- Fragment-based bispecific antibodies
- T-cell Engagers (TCEs)
- BiTEs (Bispecific T-cell Engagers)
- Trispecific antibodies
- CrossMAb
- Quadroma
Our Immune Response Screening Methods
ELISA
Quantify the antibody response against the target antigen in serum samples.
Western Blot
Assess the specificity and reactivity of the generated antibodies to the target protein in complex biological samples.
Flow Cytometry
Analyze the binding of antibodies to cell surface antigens, providing data on antibody specificity and binding affinity.
Immunohistochemistry
Examines the ability of antibodies to recognize target antigens in tissue sections, ensuring their applicability in histological studies.
Why Choose Us?
Tailored Solutions
Advanced Technology
Professional Expertise
Collaborative Approach
Alfa Cytology is a solution provider dedicated to helping our clients meet the key challenges encountered in the field of pancreatic cancer research. We offer a full suite of custom bispecific antibody services against a variety of antigens, and based on your application needs for these antibodies, our scientists will design custom immunization, screening, and purification strategies. Please contact us for more information.
Reference
- Sun Y, et al. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharmaceutica Sinica B. 2023, 13(9): 3583-3597.
